Imatinib Dose Escalation for Chronic-Phase CML
Expert Perspectives with Hagop Kantarjian, MD Interview conducted by Lee Lokey, MD
Hagop Kantarjian, MD Professor of Medicine and Chairman of the Department of Leukemia The University of Texas M. D. Anderson Cancer Center Houston, Texas, USA
This independent medical education activity features an expert interview with Hagop Kantarjian, MD, that focuses on important data from 2 manuscripts in recent literature regarding the management of chronic phase CML (Cancer.2009;115:551-560 and Blood.2009;113:2154-2160).
Dr Kantarjian briefly discusses the criteria for imatinib dose escalation, efficacy of the imatinib dose escalation, and the resulting durable cytogentic responses in patients with cytogenetic failure to standard-dose imatinib.
Q&A: Dr Kantarjian invites you to submit questions on this topic.
Disclaimer: The information on this site is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the webcast and slides. This site may contain information on products outside the approved indications where you practice.
This Webcast is available from 8 June 2009 to 8 June 2010.
This activity is supported by an unrestricted education grant from Novartis Oncology.
